(NASDAQ: ORGO) Organogenesis Holdings's forecast annual revenue growth rate of -19.04% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 11.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.47%.
Organogenesis Holdings's revenue in 2026 is $514,704,000.On average, 4 Wall Street analysts forecast ORGO's revenue for 2026 to be $37,123,893,843, with the lowest ORGO revenue forecast at $35,523,182,466, and the highest ORGO revenue forecast at $38,370,750,214. On average, 4 Wall Street analysts forecast ORGO's revenue for 2027 to be $44,309,080,604, with the lowest ORGO revenue forecast at $41,802,500,409, and the highest ORGO revenue forecast at $46,437,357,628.
In 2028, ORGO is forecast to generate $48,798,535,584 in revenue, with the lowest revenue forecast at $45,774,683,706 and the highest revenue forecast at $51,422,209,617.